

Idera Pharmaceuticals Inc (IDRA) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/IDD5990DE98EN.html>

Date: May 2021

Pages: 49

Price: US\$ 125.00 (Single User License)

ID: IDD5990DE98EN

Abstracts

Idera Pharmaceuticals Inc (IDRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Idera Pharmaceuticals Inc (Idera) is a clinical-stage biopharmaceutical company, which focuses on the discovery, development and commercialization of therapeutic drug candidates for the treatment of cancer and rare diseases. It is developing Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125) for the treatment of cancer. TLR agonists are key receptors of immune system and potential therapeutic targets for various diseases. Its clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9, in the phase III trials for the treatment of anti-PD1 refractory metastatic melanoma in combination with ipilimumab. Intratumoral tilsotolimod in combination with nivolumab is in the phase II trials for the treatment of multiple solid tumors. Idera is headquartered in Exton, Pennsylvania, the US.

Idera Pharmaceuticals Inc Key Recent Developments

Apr 29,2021: Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

Mar 01,2021: Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Nov 17,2020: Idera Pharmaceuticals announces Dan Soland to join as Chief Operating

Officer

Oct 29,2020: Idera Pharmaceuticals reports third quarter financial results and provides corporate update

Aug 04,2020: Idera Pharmaceuticals reports second quarter financial results and provides corporate update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage,

financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Idera Pharmaceuticals Inc - Key Facts
Idera Pharmaceuticals Inc - Key Employees
Idera Pharmaceuticals Inc - Key Employee Biographies
Idera Pharmaceuticals Inc - Major Products and Services
Idera Pharmaceuticals Inc - History
Idera Pharmaceuticals Inc - Company Statement
Idera Pharmaceuticals Inc - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
Idera Pharmaceuticals Inc - Business Description
Idera Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Idera Pharmaceuticals Inc - Strengths
Idera Pharmaceuticals Inc - Weaknesses
Idera Pharmaceuticals Inc - Opportunities
Idera Pharmaceuticals Inc - Threats
Idera Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD
2021
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD

2021

Idera Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 29, 2021: Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

Mar 01, 2021: Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Nov 17, 2020: Idera Pharmaceuticals announces Dan Soland to join as Chief Operating Officer

Oct 29, 2020: Idera Pharmaceuticals reports third quarter financial results and provides corporate update

Aug 04, 2020: Idera Pharmaceuticals reports second quarter financial results and provides corporate update

Apr 30, 2020: Idera Pharmaceuticals reports first quarter financial results and provides corporate update

Jan 14, 2020: Idera Pharmaceuticals provides 2020 update and outlook

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Idera Pharmaceuticals Inc, Key Facts

Idera Pharmaceuticals Inc, Key Employees

Idera Pharmaceuticals Inc, Key Employee Biographies

Idera Pharmaceuticals Inc, Major Products and Services

Idera Pharmaceuticals Inc, History

Idera Pharmaceuticals Inc, Key Competitors

Idera Pharmaceuticals Inc, Ratios based on current share price

Idera Pharmaceuticals Inc, Annual Ratios

Idera Pharmaceuticals Inc, Annual Ratios (Cont...1)

Idera Pharmaceuticals Inc, Interim Ratios

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Idera Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List Of Figures

LIST OF FIGURES

Idera Pharmaceuticals Inc, Performance Chart (2016 - 2020)

Idera Pharmaceuticals Inc, Ratio Charts

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Idera Pharmaceuticals Inc (IDRA) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/IDD5990DE98EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IDD5990DE98EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970